[ad_1]
J&J said a booster dose of its COVID-19 vaccine provides a rapid and potent rise in antibodies, supporting the use of a second dose of the single-dose vaccine.
Today, Wednesday, the company reported that a second dose of the J&J vaccine led to a nine-fold increase in antibodies that fight the virus, compared to levels achieved by participants in the experiment 28 days after receiving the vaccine. first dose, citing provisional data. from an early stage experience.
Participants received the booster dose six months after receiving the first dose, according to J&J. Significant increases in antibody responses were seen in people aged 18 to 55 years and in those 65 years and older who received a lower dose of the booster.
Mathai Mamin, global head of research and development at J & J’s Janssen Pharmaceuticals, said the latest findings, along with data showing the durability of a single dose over at least eight months, underscore the future booster dosing strategy.
“We look forward to discussing a potential recall strategy for our Johnson & Johnson vaccine with public health officials eight months or more after the primary single dose vaccination,” he added in a statement.
WHO position
Health experts around the world are engaged in a debate over when a booster dose of coronavirus vaccines will be needed and who should receive them first. Many countries have yet to vaccinate a tenth of their population, prompting the World Health Organization to call on governments to delay giving booster doses until more people are protected around the world.
Meanwhile, the United States this month announced plans to start providing boosters to some recipients of the Pfizer and Moderna vaccines, starting September 20.
The Biden administration expects 100 million booster doses of so-called mRNA vaccines to be in place by the end of 2021.
More than 14 million U.S. residents have received an injection of the J&J vaccine, according to the Centers for Disease Control and Prevention.
Another dose is needed
Public health and medical experts from the US Department of Health and Human Services said on Aug. 18 that they likely expected a need for booster doses of the J&J vaccine.
HHS officials said in a statement: “The administration of the J&J vaccine in the United States did not begin until March 2021, and we expect more data on the vaccine in the coming weeks …”.
Johnson & Johnson have confirmed that their vaccine offers strong protection. He said in July that recipients of his vaccine produced strong neutralizing antibodies for at least eight months against all variants, including delta.
At the time, Johan van Hoof, global head of infectious diseases and vaccines at Johnson & Johnson, said a booster would likely not be needed for another year after the first, but the company would follow the data. J&J is also awaiting the results of an advanced stage study of the two-dose regimen, two months apart.
Since the J&J vaccine was approved in late February, boosters are unlikely to be given before the end of the year.
Source link
